Til Menge - Publications

Department of Neurology Heinrich-Heine-University Düsseldorf, Germany 

52 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C. Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. Frontiers in Neurology. 8: 305. PMID 28729851 DOI: 10.3389/fneur.2017.00305  0.68
2016 Menge T, Dubey D, Warnke C, Hartung HP, Stüve O. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics. PMID 27552111 DOI: 10.1080/14737175.2016.1227242  0.64
2016 Menge T, Meyer Zu Hörste G. Current research | Aktuelles aus der Forschung Aktuelle Neurologie. 43: 53-54. DOI: 10.1055/s-0042-100566  0.68
2015 Menge T. Vaccinations do not cause multiple sclerosis | Impfungen lösen wohl keine MS aus Mmw Fortschritte Der Medizin. 157: 45. PMID 26759880  0.68
2015 Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics. 15: 339-46. PMID 25800129 DOI: 10.1586/14737175.2015.1025755  0.68
2015 Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Costa GD, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, ... ... Menge T, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 1013-24. PMID 25680984 DOI: 10.1177/1352458514568827  0.68
2015 Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T, Keller A, Backes C, Beier M, Scheffler M, Dehmel T, Kieseier BC, Hartung HP, Küry P, Aktas O. Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. Annals of Clinical and Translational Neurology. 2: 43-55. PMID 25642434 DOI: 10.1002/acn3.152  0.68
2015 Menge T, Meyer Zu Hörste G. Aktuelles aus der Forschung Aktuelle Neurologie. 42: 293-294. DOI: 10.1055/s-0035-1552637  0.68
2014 Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A, Havrdova E, Tumani H, Bertolotto A, Comabella M, Frederiksen J, Álvarez-Cermeño JC, Villar L, ... ... Menge T, et al. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology. 83: 1210-6. PMID 25150289 DOI: 10.1212/WNL.0000000000000809  0.68
2014 Menge T. What do multiple sclerosis patients actually die from? | Woran sterben MS-patienten eigentlich? Mmw-Fortschritte Der Medizin. 156: 34. PMID 24934048  0.68
2014 Menge T, Stüve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology. 83: 87-97. PMID 24920854 DOI: 10.1212/WNL.0000000000000540  0.68
2014 Hartung HP, Aktas O, Menge T, Kieseier BC. Immune regulation of multiple sclerosis. Handbook of Clinical Neurology. 122: 3-14. PMID 24507511 DOI: 10.1016/B978-0-444-52001-2.00001-7  0.68
2014 Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clinical and Experimental Immunology. 175: 397-407. PMID 24102425 DOI: 10.1111/cei.12206  0.68
2014 Menge T, Meyer Zu Hörste G. Research news | Aktuelles aus der Forschung Aktuelle Neurologie. 41: 531-532. DOI: 10.1055/s-0033-1349527  0.68
2013 Ringelstein M, Harmel J, Distelmaier F, Ingwersen J, Menge T, Hellwig K, Kieseier B, Mayatepek E, Hartung HP, Kuempfel T, Aktas O. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: Infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum Multiple Sclerosis Journal. 19: 1544-1547. PMID 23886825 DOI: 10.1177/1352458513498125  0.68
2013 Teunissen C, Menge T, Altintas A, Álvarez-Cermeño JC, Bertolotto A, Berven FS, Brundin L, Comabella M, Degn M, Deisenhammer F, Fazekas F, Franciotta D, Frederiksen JL, Galimberti D, Gnanapavan S, et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1802-9. PMID 23695446 DOI: 10.1177/1352458513488232  0.68
2013 Warnke C, Meyer Zu Hörste G, Menge T, Stüve O, Hartung HP, Wiendl H, Kieseier BC. Teriflunomide for treatment of multiple sclerosis | Teriflunomid zur Behandlung der Multiplen Sklerose Nervenarzt. 84: 724-731. PMID 23695001 DOI: 10.1007/s00115-013-3779-7  0.68
2013 Menge T, Hörste GMZ. Latest from research | Aktuelles aus der Forschung Aktuelle Neurologie. 40: 166-167. DOI: 10.1055/s-0032-1333041  0.68
2012 Menge T, Cree B, Saleh A, Waterboer T, Berthele A, Kalluri SR, Hemmer B, Aktas O, Hartung HP, Methner A, Kieseier BC. Neuromyelitis optica following human papillomavirus vaccination. Neurology. 79: 285-7. PMID 22722628 DOI: 10.1212/WNL.0b013e31825fdead  0.68
2012 Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J, Hemmer B, Stüve O. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Current Pharmaceutical Design. 18: 209-19. PMID 22229582 DOI: 10.2174/138161212799040501  0.68
2012 Menge T, Kieseier BC, Warnke C, Aktas O, Hartung HP. Alemtuzumab: A further option for treatment of multiple sclerosis | Alemtuzumab: Eine weitere chance zur therapie der multiplen sklerose Nervenarzt. 83: 487-501. PMID 22038387 DOI: 10.1007/s00115-011-3393-5  0.68
2012 Menge T, Meyer Zu Hörste G. News from research | Aktuelles aus der Forschung Aktuelle Neurologie. 39: 486-487. DOI: 10.1055/s-0032-1327290  0.68
2011 Menge T, Lalive PH, von Büdingen HC, Genain CP. Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. Journal of Neuroinflammation. 8: 161. PMID 22093619 DOI: 10.1186/1742-2094-8-161  0.68
2011 Menge T, Hartung HP, Kieseier BC. Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al. Journal of Neurology. 258: 904-7. PMID 21340521 DOI: 10.1007/s00415-011-5941-0  0.68
2011 Lalive PH, Häusler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, Schroeter M, Hartung HP, Kieseier BC, Menge T. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children Multiple Sclerosis Journal. 17: 297-302. DOI: 10.1177/1352458510389220  0.68
2010 Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, Bennett JL, Berthele A, Hemmer B. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Archives of Neurology. 67: 1201-8. PMID 20937947 DOI: 10.1001/archneurol.2010.269  0.68
2010 Sominanda A, Lundkvist M, Fogdell-Hahn A, Hemmer B, Hartung HP, Hillert J, Menge T, Kieseier BC. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Archives of Neurology. 67: 1095-101. PMID 20837854 DOI: 10.1001/archneurol.2010.218  0.68
2010 Sellner J, Cepok S, Kalluri SR, Nestler A, Kleiter I, Kümpfel T, Linker R, Melms A, Menge T, Tumani H, Paul F, Hemmer B, Berthele A. Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochemistry International. 57: 662-7. PMID 20705110 DOI: 10.1016/j.neuint.2010.08.003  0.68
2010 Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Archives of Neurology. 67: 923-30. PMID 20697042 DOI: 10.1001/archneurol.2010.161  0.68
2010 Wolf C, Menge T, Stenner MP, Meyer zu Hörste G, Saleh A, Hartung HP, Wiendl H, Kieseier BC. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Archives of Neurology. 67: 881-3. PMID 20625098 DOI: 10.1001/archneurol.2010.143  0.68
2010 Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G, Erten G, Espiño M, ... ... Menge T, et al. Neurofilament ELISA validation. Journal of Immunological Methods. 352: 23-31. PMID 19857497 DOI: 10.1016/j.jim.2009.09.014  0.68
2009 Menge T, Schloot NC, Schott M, Hemmer B, Wiendl H, Roden M, Hartung HP, Kieseier BC. Interferon beta treatment does not induce organ-specific autoantibodies in multiple sclerosis Neurology. 73: 900-902. PMID 19752459 DOI: 10.1212/WNL.0b013e3181b78460  0.68
2009 Stüve O, Leussink VI, Fröhlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Archives of Neurology. 66: 259-61. PMID 19204165 DOI: 10.1001/archneurol.2008.551  0.68
2009 Menge T, Büdingen HC, Dalakas MC, Kieseier BC, Hartung HP. Targeting B cells in multiple sclerosis. Current concepts and strategies | B-zell-gerichtete multiple-sklerose-therapie. Aktueller stand Nervenarzt. 80: 190-198. PMID 19189075 DOI: 10.1007/s00115-008-2664-2  0.68
2008 Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 68: 2445-68. PMID 19016573 DOI: 10.2165/0003495-200868170-00004  0.68
2008 Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. Pharmacological treatment of early multiple sclerosis. Drugs. 68: 73-83. PMID 18081373  0.68
2007 Menge T, von Büdingen HC, Lalive PH, Genain CP. Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid-phase ELISA. European Journal of Immunology. 37: 3229-39. PMID 17918203 DOI: 10.1002/eji.200737249  0.68
2007 Menge T, Kieseier BC, Nessler S, Hemmer B, Hartung HP, Stüve O. Acute disseminated encephalomyelitis: an acute hit against the brain. Current Opinion in Neurology. 20: 247-54. PMID 17495616 DOI: 10.1097/WCO.0b013e3280f31b45  0.68
2007 Menge T, Hemmer B, Nessler S, Zhou D, Kieseier BC, Hartung HP. Immunopathogenesis of multiple sclerosis: Overview Immune Regulation and Immunotherapy in Autoimmune Disease. 171-187. DOI: 10.1007/978-0-387-36003-4_10  0.68
2006 Gardell JL, Dazin P, Islar J, Menge T, Genain CP, Lalive PH. Apoptotic effects of Human Herpesvirus-6A on glia and neurons as potential triggers for central nervous system autoimmunity. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 37: S11-6. PMID 17276360 DOI: 10.1016/S1386-6532(06)70005-1  0.68
2006 Lalive PH, Menge T, Barman I, Cree BA, Genain CP. Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays Neurology. 67: 176-177. PMID 16832107 DOI: 10.1212/01.wnl.0000223346.09426.34  0.68
2006 von Büdingen HC, Menge T, Hauser SL, Genain CP. Restrictive and diversifying elements of the anti-myelin/oligodendrocyte glycoprotein antibody response in primate experimental allergic encephalomyelitis. Immunogenetics. 58: 122-8. PMID 16528499 DOI: 10.1007/s00251-006-0100-y  0.68
2006 Lalive PH, Menge T, Delarasse C, Della Gaspera B, Pham-Dinh D, Villoslada P, von Büdingen HC, Genain CP. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 103: 2280-5. PMID 16461459 DOI: 10.1073/pnas.0510672103  0.68
2005 Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O, Hartung HP, Kieseier BC, Stüve O. Acute disseminated encephalomyelitis: an update. Archives of Neurology. 62: 1673-80. PMID 16286539 DOI: 10.1001/archneur.62.11.1673  0.68
2005 Menge T, Lalive PH, von Büdingen HC, Cree B, Hauser SL, Genain CP. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. The Journal of Allergy and Clinical Immunology. 116: 453-9. PMID 16083805 DOI: 10.1016/j.jaci.2005.03.023  0.68
2005 Menge T, Hartung HP, Stüve O. Statins--a cure-all for the brain? Nature Reviews. Neuroscience. 6: 325-31. PMID 15803163 DOI: 10.1038/nrn1652  0.68
2005 Menge T, Von Büdingen HC, Zamvil SS, Hartung HP, Kieseier BC, Stüve O. Statins for treatment of CNS diseases. Status report from research and clinical practice | Statine zur behandlung von erkrankungen des zentralen nervensystems. Eine standortbestimmung aus forschung und klinik Nervenarzt. 76: 426-437. PMID 15448914 DOI: 10.1007/s00115-004-1806-4  0.68
2004 von Büdingen HC, Hauser SL, Ouallet JC, Tanuma N, Menge T, Genain CP. Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. European Journal of Immunology. 34: 2072-83. PMID 15259004 DOI: 10.1002/eji.200425050  0.68
2002 Menge T, Rzepka R, Melchers I. Monoclonal autoantibodies from patients with autoimmune diseases: specificity, affinity and crossreactivity of MAbs binding to cytoskeletal and nucleolar epitopes, cartilage antigens and mycobacterial heat-shock protein 60. Immunobiology. 205: 1-16. PMID 11999339 DOI: 10.1078/0171-2985-00107  0.68
2002 Jander S, Bussini S, Neuen-Jacob E, Bosse F, Menge T, Müller HW, Stoll G. Osteopontin: a novel axon-regulated Schwann cell gene. Journal of Neuroscience Research. 67: 156-66. PMID 11782959 DOI: 10.1002/jnr.10099  0.68
2001 Menge T, Jander S, Stoll G. Induction of the proinflammatory cytokine interleukin-18 by axonal injury Journal of Neuroscience Research. 65: 332-339. PMID 11494369 DOI: 10.1002/jnr.1158  0.68
2000 Menge T, Neumann-Haefelin T, Von Giesen HJ, Arendt G. Progressive stroke in an HIV-1-positive patient under protease inhibitors European Neurology. 44: 252-254. PMID 11096229  0.68
Show low-probability matches.